-DOCSTART- -X- O
OBJECTIVES -X- _ O
: -X- _ O
The -X- _ O
emergence -X- _ O
of -X- _ O
the -X- _ O
pandemic -X- _ O
influenza -X- _ O
A -X- _ O
( -X- _ O
H1N1 -X- _ O
) -X- _ O
pdm09 -X- _ O
virus -X- _ O
in -X- _ O
2009 -X- _ O
saw -X- _ O
a -X- _ O
significant -X- _ O
increase -X- _ O
in -X- _ O
the -X- _ O
therapeutic -X- _ O
and -X- _ O
prophylactic -X- _ O
use -X- _ O
of -X- _ O
neuraminidase -X- _ O
inhibitors -X- _ O
( -X- _ O
NAIs -X- _ O
) -X- _ O
to -X- _ O
mitigate -X- _ O
the -X- _ O
impact -X- _ O
of -X- _ O
this -X- _ O
highly -X- _ O
transmissible -X- _ O
virus. -X- _ O
Prior -X- _ O
to -X- _ O
the -X- _ O
pandemic -X- _ O
, -X- _ O
many -X- _ O
countries -X- _ O
stockpiled -X- _ O
NAIs -X- _ O
and -X- _ O
developed -X- _ O
pandemic -X- _ O
plans -X- _ O
for -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
antiviral -X- _ O
drugs -X- _ O
, -X- _ O
based -X- _ O
on -X- _ O
either -X- _ O
treatment -X- _ O
of -X- _ O
high-risk -X- _ O
individuals -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
prophylaxis -X- _ O
of -X- _ O
contacts. -X- _ O
However -X- _ O
, -X- _ O
to -X- _ O
date -X- _ O
there -X- _ O
has -X- _ O
been -X- _ O
a -X- _ O
lack -X- _ O
of -X- _ O
in -X- _ O
vivo -X- _ O
models -X- _ O
to -X- _ O
test -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
treatment -X- _ O
or -X- _ O
prophylaxis -X- _ O
with -X- _ O
NAIs -X- _ O
, -X- _ O
for -X- _ O
influenza- -X- _ O
infected -X- _ O
individuals -X- _ O
or -X- _ O
exposed -X- _ O
contacts -X- _ O
, -X- _ O
in -X- _ O
a -X- _ O
household -X- _ O
setting. -X- _ O
METHODS -X- _ O
: -X- _ O
A -X- _ O
ferret -X- _ B-Patient
model -X- _ I-Patient
of -X- _ O
household -X- _ O
contact -X- _ O
was -X- _ O
developed -X- _ O
to -X- _ O
study -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
different -X- _ B-Intervention
prophylaxis -X- _ I-Intervention
regimens -X- _ I-Intervention
in -X- _ O
preventing -X- _ O
infection -X- _ O
in -X- _ O
contact -X- _ O
ferrets -X- _ O
exposed -X- _ O
to -X- _ O
influenza -X- _ O
A -X- _ O
( -X- _ O
H1N1 -X- _ O
) -X- _ O
pdm09-infected -X- _ O
index -X- _ O
ferrets. -X- _ O
RESULTS -X- _ O
: -X- _ O
Among -X- _ O
the -X- _ O
different -X- _ O
prophylactic -X- _ O
regimens -X- _ O
, -X- _ O
contact -X- _ B-Outcome
ferrets -X- _ I-Outcome
receiving -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
prophylaxis -X- _ I-Outcome
twice -X- _ I-Outcome
daily -X- _ I-Outcome
showed -X- _ I-Outcome
better -X- _ I-Outcome
outcomes -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
receiving -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
once -X- _ I-Outcome
daily. -X- _ I-Outcome
Benefits -X- _ I-Outcome
included -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
delay -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
time -X- _ I-Outcome
to -X- _ I-Outcome
secondary -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
lower -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
and -X- _ I-Outcome
higher -X- _ I-Outcome
activity -X- _ I-Outcome
levels. -X- _ I-Outcome
The -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
index -X- _ I-Outcome
ferrets -X- _ I-Outcome
at -X- _ I-Outcome
36 -X- _ I-Outcome
h -X- _ I-Outcome
post-infection -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
influence -X- _ I-Outcome
either -X- _ I-Outcome
secondary -X- _ I-Outcome
infection -X- _ I-Outcome
rates -X- _ I-Outcome
or -X- _ I-Outcome
clinical -X- _ I-Outcome
symptoms -X- _ I-Outcome
in -X- _ I-Outcome
exposed -X- _ I-Outcome
contact -X- _ I-Outcome
ferrets. -X- _ I-Outcome
Neither -X- _ I-Outcome
prophylaxis -X- _ I-Outcome
nor -X- _ I-Outcome
treatment -X- _ I-Outcome
prevented -X- _ I-Outcome
infection -X- _ I-Outcome
or -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
shedding -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
clinical -X- _ I-Outcome
symptoms -X- _ I-Outcome
did -X- _ I-Outcome
improve -X- _ I-Outcome
in -X- _ I-Outcome
infected -X- _ I-Outcome
animals -X- _ I-Outcome
receiving -X- _ I-Outcome
prophylaxis. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Different -X- _ O
oseltamivir -X- _ O
prophylaxis -X- _ O
regimens -X- _ O
did -X- _ O
not -X- _ O
prevent -X- _ O
infections -X- _ O
, -X- _ O
but -X- _ O
consistently -X- _ O
resulted -X- _ O
in -X- _ O
a -X- _ O
reduction -X- _ O
in -X- _ O
symptoms -X- _ O
in -X- _ O
infected -X- _ O
ferrets. -X- _ O
However -X- _ O
, -X- _ O
oseltamivir -X- _ O
prophylaxis -X- _ O
failed -X- _ O
to -X- _ O
reduce -X- _ O
viral -X- _ O
titres -X- _ O
, -X- _ O
which -X- _ O
warrants -X- _ O
further -X- _ O
investigation -X- _ O
in -X- _ O
humans -X- _ O
. -X- _ O

